

Carvedilol- β -cyclodextrin Systems: Preparation, Characterization and *in vitro* Evaluation

Anshu Sharma¹ and C.P. Jain²

¹Bhupal Nobles' College of Pharmacy, Udaipur - 313 001, Rajasthan, India.

²Department of Pharmaceutical Sciences, MohanLal Sukhadia University, Udaipur-313 001, Rajasthan, India.

ABSTRACT: The purpose of this study was to improve the solubility and dissolution rate of carvedilol by forming a complex with β -cyclodextrin. Phase solubility diagrams revealed increase in solubility of the drug upon cyclodextrin addition, showing A_N type curve. Complexation of carvedilol was carried out with β -cyclodextrin by physical mixing, kneading and co-precipitation method. The prepared complexes and physical mixture were characterized by Fourier transform infra red spectroscopy, differential scanning calorimetry, powder X-ray diffractometry and inclusion efficiency. It was also observed that the complexes exhibit higher dissolution rates than the pure drug and physical mixture. Among all carvedilol-cyclodextrin complexes, inclusion complex (1:5) prepared by co-precipitation method showed better release.

Key words: Carvedilol, β -cyclodextrin, dissolution; solubility; stability study

INTRODUCTION

Cyclodextrins (CDs) have been developing increasing interest in the pharmaceutical field because of their ability to modify physical, chemical and biological properties of a number of hydrophobic drug molecules through the formation of inclusion complexes.¹⁻³ They have been widely used as complexing agents to modify drug solubility or improve drug stability, and bioavailability, by means of drug inclusion into the hydrophobic cavity of cyclodextrin. CDs are thus offering new hope to formulation scientists in their efforts to develop an effective drug delivery system. CDs are effectively used as drug carriers and in foods and flavors, cosmetics, packing materials, textiles, separation processes, environmental protection efforts, fermentation, and catalysis.⁴⁻⁵

CDs are cyclic oligosaccharides consisting of (α -1,4)-linked α -D-glucopyranose units, with a relatively hydrophobic central cavity and a hydrophilic outer surface. The most abundant natural

CDs are α -cyclodextrin (α -CD), β -cyclodextrin (β -CD), and γ -cyclodextrin (γ -CD), containing 6, 7, and 8 glucopyranose units, respectively. The hydrophilic exterior surface of the CD molecules makes them water-soluble, but the hydrophobic cavity provides a microenvironment for appropriately sized nonpolar molecules. CDs are capable of forming inclusion complexes with many drugs by including a whole drug molecule, or only some nonpolar part of it, inside their cavity. In an aqueous solution, the complexes are readily dissociated and free drug molecules are in relatively rapid dynamic equilibrium with drug molecules bound within the CD cavity.⁶⁻⁹

Carvedilol competitively blocks β_1 , β_2 and α_1 receptors. It lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through blockade. Carvedilol is used in the management of hypertension and angina pectoris, and as an adjunct to standard therapy in symptomatic heart failure. Carvedilol belongs to class II of the Biopharmaceutical classification systems, as it demonstrates poor solubility and high permeability.¹⁰⁻¹¹ The major drawback with

Correspondence to: Anshu Sharma
E-mail: anshukiransharma@gmail.com

carvedilol therapy is its poor aqueous solubility and dissolution in gastric fluid. Hence it is aimed to enhance the aqueous solubility and dissolution rate of carvedilol by forming an inclusion complex with β -CD.

In the present study carvedilol and β -CD binary systems were prepared according to different techniques (physical mixing, kneading and co-precipitation method) and characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and Fourier transform infrared (FTIR) spectroscopy in order to achieve an improvement on carvedilol dissolution properties useful for different applications.

MATERIALS AND METHODS

Materials

Carvedilol was provided by Sun Pharmaceutical Ltd., Baroda, India as a gift sample and β -CD was purchased from Hi-Media Laboratories Pvt. Ltd., Mumbai, India. All other chemicals and reagents used were of analytical grade.

Methods

Preparation of physical mixture by trituration method. Carvedilol and β -CD in the ratio of 1:1, 1:3, 1:5 were sifted through a 40-mesh (425 μ m) screen, mixed together (with trituration in a pestle mortar), and stored in a desiccated environment.¹²

Preparation of complexes by coprecipitation method. Carvedilol and β -CD were taken in ratio of 1:1, 1:3 and 1:5. The β -CD was dissolved in adequate volume of methanol. The solvent was then rapidly evaporated with the aid of mild heat (up to about 50°C) and surface airflow with constant vigorous stirring to form a uniform solid mass. The co-precipitate was crushed and desiccated under vacuum for 24 h, pulverized (again, after formation of a more fragile mass), vacuum desiccated again for a day, sized into different sieve fractions and stored in a desiccators, until further use.¹³

Preparation of complexes by kneading method. Kneaded complexes were prepared by wetting physical mixture in different ratio of 1:1, 1:3

and 1:5 in mortar in least amount of methanol-water mixture (in 1%v/v) and kneading thoroughly with a pestle to obtain a homogenous paste which was then dried in oven at 40°C for 48 hours. The dried complexes were pulverized into a fine powder and stored in a desiccator until further evaluation.¹⁴

Phase solubility studies. The phase solubility studies of carvedilol at various concentration of β -CD was studied by the method reported by Higuchi and Connors.¹⁵ An excess amount of the drug was added to 10 ml volumetric flask containing increasing concentration of β -CD, in the range of 2 mM to 14mM aqueous solution. The samples were allowed to shake for 48 h at $25 \pm 1^\circ\text{C}$, until the equilibrium was established. The solutions were filtered through membrane filter (0.45 μ). After 48 h, the carvedilol concentration was determined spectrophotometrically at 288 nm using Shimadzu UV 1800, Japan. The apparent 1:1 stability constants, $K_{c1:1}$, were calculated from the linear portion of phase solubility diagrams using the equation:

$$K_{c1:1} = \text{slope}/S_0(1-\text{slope})$$

where S_0 is the drug solubility in the absence of β -CD (intercept).

Inclusion efficiency study. All inclusion complexes of carvedilol and their physical mixtures (25 mg) were separately taken in 25-ml volumetric flasks. Ten milliliters of methanol were added to it, mixed thoroughly, and sonicated for 30 min at ambient temperature. The volume was made up to mark with methanol. An aliquot from each of the solution was suitably diluted with methanol to get the final concentration of 10 $\mu\text{g/ml}$ of drug and spectrophotometrically assayed for drug content. Inclusion efficiency was calculated using the formula.¹⁶

Inclusion efficiency = (estimated % drug content/ theoretical % drug content) x 100

Fourier transform infrared spectroscopy. Fourier transform infrared spectra of carvedilol, β -CD, physical mixtures and complexes were obtained using Shimadzu FTIR-8400S spectrometer, Japan. Samples of carvedilol, β -CD, physical mixtures and complexes were ground and mixed

thoroughly with potassium bromide at a 1:5 sample/KBr ratio. The KBr discs were prepared by compressing the powders at a pressure of 5 T for 5 min in a hydraulic press. The scanning range was 40 to 4000 cm^{-1} and the resolution was 4 cm^{-1} .

Differential scanning calorimetry (DSC). Thermal characteristics of the complexes were determined using a DSC analysis of the samples, carried out on a Perkin-Elmer DSC7, USA. Samples (6.5-10 mg) were accurately weighed and heated on a closed aluminum pan at a heating rate of 10°C/min over the temperature range of 5 and 300°C. DSC analysis was carried out under nitrogen gas flow of 20 lb/in^2 .

Powder X-ray diffraction (PXRD). PXRD patterns were recorded using Philips PW 1729 X-ray generator, USA fitted with a copper target, a voltage of 40 kV, and a current of 30 mA. The scanning rate was 1°/min over a 2 θ range of 1-50°. PXRD patterns were traced for pure drug, CD, physical mixture, solid dispersions and CD complexes. The samples were slightly ground and packed into the aluminum sample container.

In vitro studies. The release rate of carvedilol from physical mixtures and complexes was determined using United States Pharmacopoeia (USP) Dissolution Testing Apparatus 2 (paddle method; Veeco Scientific, Mumbai, India). The dissolution test was performed using simulated gastric fluid for carvedilol at $37 \pm 0.5^\circ\text{C}$ and 50 rpm for 90 minutes. A 5 ml aliquot was withdrawn at different time intervals and filtered using a 0.45 μ nylon disc filter; each sample was replaced with 5 ml of fresh dissolution medium. The filtered samples were suitably diluted, if necessary and assayed by measuring the absorbance spectrophotometrically at 288 nm.

RESULT AND DISCUSSION

Phase solubility studies. The phase-solubility diagram for complex formation between carvedilol and β -CD is presented in Figure 1. According to the Higuchi and Connors classification, the diagram shows the A_N type curve where the solubility

increases linearly with CD concentration and further deviates negatively at higher concentrations. The interaction mechanism for the A_N type curve is complicated because of a significant contribution of solute-solvent interaction to the complexation. The negative deviation from linearity may be associated with CD induced changes in the dielectric constant of the aqueous complexation media, changes in complex solubility and/or self-association of CD molecules. It can be seen from the curve that the apparent solubility of carvedilol increased linearly due to the formation of a soluble inclusion complex between carvedilol and β -CD.




Figure 1. Phase solubility studies of Carvedilol.

In the region where a linear increase was observed, a linear regression analysis was performed and the stoichiometry of the complexes was assumed to be 1:1. The apparent association constant ($K_{C_{1:1}}$) often plays an important role in explaining the various results obtained. The K_c for the complex formed was calculated from the slope (Higuchi and Connors, 1965).

The value of the stability constant $K_{C_{1:1}}$ was 610 M^{-1} for carvedilol, well within the range of 100 to 1000 M^{-1} considered as ideal. A smaller $K_{C_{1:1}}$ value indicates too weak an interaction, whereas a larger value indicates the possibility of limited release of drug from the complex thereby interfering with drug absorption.

Inclusion efficiency study. The inclusion efficiency of the drug in β -CD was determined based on the differential solubility of free drug and complexed drug. The results of inclusion efficiency study are shown in Table 1. The data indicate that the percent inclusion efficiency of 1:5 inclusion

complexes prepared by co-precipitation method was $98.6\% \pm 1.5$, whereas other inclusion complexes prepared by kneading method and physical mixtures have values in the range of 53.5 ± 1.5 to 84.6 ± 1.53 suggesting that drug was uniformly distributed in all 1:5 inclusion complex whereas the inclusion complexes and physical mixtures prepared in other ratios did not show satisfactory drug incorporation. Physical mixture and complex prepared by kneading and coprecipitation method having ratio 1:5 were further selected for FTIR, DSC, PXRD, in-vitro and stability studies.

Table 1. Inclusion efficiency study of carvedilol complexes and physical mixtures with β -cyclodextrin.

Methods	Ratio	% Inclusion efficiency \pm SD
Co-precipitation method	1:1	76.3 \pm 2.12
	1:3	86.2 \pm 2.23
	1:5	98.6 \pm 1.50
Kneading method	1:1	65.36 \pm 2.31
	1:3	77.96 \pm 1.87
	1:5	84.6 \pm 1.53
Physical Mixture	1:1	53.5 \pm 1.50
	1:3	62.6 \pm 0.81
	1:5	67.5 \pm 1.2

Fourier transform infrared spectroscopy. The FTIR analysis is a useful technique to assess the

interaction and the complex formation between drug molecules and CD in the solid state. This allows the detection of complex formations in solid phase and to point out the implication of the different functional groups of the guest and host molecules in the inclusion process, by analysing the significant changes in the shape and position of the absorbance bands. Shifts or intensity changes in the characteristic bands of pure substance are considered as evidence of the complex existence.¹⁷

Carvedilol showed characteristic peaks at 3346.27 cm^{-1} (O-H and N-H stretching vibration peaks merged together), 2925.81 cm^{-1} (C-H stretching vibrations), 1598.88 cm^{-1} (N-H bending vibrations) and 1253.64 cm^{-1} (O-H bending and C-O stretching vibrations). The spectrum of β -CD displayed a broad band between 3100 cm^{-1} and 3800 cm^{-1} attributed to free OH from primary and secondary OH groups, between 2800 cm^{-1} and 3100 cm^{-1} corresponding to bound OH, at 1626 cm^{-1} due to water molecules present in the cavity, and a large band that displayed distinct peaks between 900 cm^{-1} and 1200 cm^{-1} , responsible for C-O vibrations. The FTIR spectra (Figure 2) of the inclusion complex prepared by co-precipitation, kneading method and




Figure 2. FTIR spectra of a) carvedilol b) β -cyclodextrin c) physical mixture d) kneaded complex e) co-precipitated complex.

physical mixture were dominated by the vibrational bands of the CD molecule. Any sign of interaction on complexation would be reflected by changes in the characteristic peaks of carvedilol, depending on the extent of interaction. The FTIR spectra of all the complexes did not show significant differences from the respective spectra of carvedilol and β -CD except shift of peak at 1253.64 cm^{-1} (O-H bending and C-O stretching vibrations) to 1252.57 cm^{-1} and 1252.12 cm^{-1} for the complexes prepared by kneading and co-precipitation method, respectively which is due to the inclusion complexes. The physical mixture exhibited a peak indicating alkyl aryl stretching at 1212.60 cm^{-1} and 1020 cm^{-1} indicating a weak interaction between carvedilol and β -CD.

Differential scanning calorimetry (DSC). DSC is a useful technique for drugs that form the inclusion complexes with β -CD. The disappearance or reduction of the endotherm related to the melting of the crystalline drug in the DSC profile of the drug/ β -CD complex is generally taken as an indication of the interaction between the components.

The DSC curve of carvedilol showed a sharp endothermic peak ($T_{\text{peak}} = 115^\circ\text{C}$) corresponding to its melting point, indicating its crystalline nature. β -CD exhibits a broad endothermic effect ranging between 30°C and 149°C associated with loss of water from inside the cavity. The thermal behavior (Figure 3) of both physical mixture and complexes of the drug was different. In case of physical mixture, the peak of carvedilol was weak, broadened and appeared at 110°C . These findings demonstrated the presence of interactions between the drug and CD system. In the complex prepared by kneading method, the peak of carvedilol appeared at 110°C but largely broadened and weak. In the DSC curve of the complex prepared by co-precipitation method, the sharp fusion peak of carvedilol was not observed, indicating the interaction the carvedilol with CD cavity, which in turn leads to an almost complete loss of crystallinity in the binary system. The differences in the thermal behavior of carvedilol in form of physical mixtures and complexes suggested the drug crystallinity decreased when prepared as complexes and that decrease was dependent on the method of preparation of complexes.




Figure 3. DSC spectra of a) carvedilol b) β -cyclodextrin c) physical mixture d) kneaded complex e) co-precipitated complex.

Powder X-ray diffraction (PXRD). Powder XRD study was used to measure the crystallinity of the formed inclusion complexes. A change in the crystallinity of the drug indicates complex formation by appearance of a new or at least deviation from the original pattern. The formation of an amorphous state proves that the drug was dispersed in a molecular state with CDs.

Numerous diffraction peaks of carvedilol were observed at 2θ of 12.8° , 15.62° , 17.46° , 18.56° , 20.1° , 24.3° and 26.2° indicating the presence of crystalline nature of carvedilol. β -CD is a very crystalline molecule with major peaks at 2θ values of 4.75° , 12.7° , 19.7° , 21.1° , 22.8° , 24.3° , and 35.9° .

XRD-scanning of physical mixture showed decreasing number of peaks with lower intensity indicating partial amorphous nature of the drug in its binary mixtures (Figure 4). In case of inclusion complex prepared by kneading method, there was a decrease in the intensity of carvedilol but the major peaks remained at the same positions. On the other hand, no diffraction peak from carvedilol was observed in complex prepared by coprecipitation method. The PXRD pattern of this complex was diffused. This result suggests that carvedilol exists in an amorphous state in the complex.




Figure 4. PXRD diffractogram of a) carvedilol b) β -cyclodextrin c) physical mixture d) kneaded complex e) co-precipitated complex.




Figure 5. Dissolution profile of physical mixtures and complexes of β -cyclodextrin with Carvedilol.

In vitro studies. The dissolution profile of pure carvedilol and β -CD complexes formed by physical mixture, kneading method and co-precipitation methods are illustrated in Figure 5. The dissolution profiles of all component exhibited first order release kinetics. All β -CD complexes exhibited higher rates of dissolution and dissolution efficiency values than pure drug, indicating rapid and higher dissolution of drug from its β -CD complexes. The drug release in 20 min for carvedilol (5.12%) was enhanced in physical mixture (50.65%), kneaded complex (90.34%) as well as in co-precipitated complex (99.36%).

Improved dissolution of the complexes was simultaneous with increased particle wettability and reduced crystallinity of the product. The surfactant-like properties of β -CD were postulated in some cases to explain the higher dissolution rate of the complexes. β -CD can reduce the interfacial tension between the solid particles of pure drug. The improvement in dissolution rate of pure drug from β -CD complexes was in agreement with the results obtained from phase solubility analysis.

The extent of the enhancement of dissolution rate was found to depend on the preparation method of the complex. The improved dissolution of the complex prepared through kneading and coprecipitation may be due to the formation of an

inclusion complex of the drug with β -CD and /or conversion of the drug to an amorphous state or nearly amorphous state supported by XRD and DSC studies. Physical mixtures demonstrated better dissolution rates because β -CD dissolves more rapidly in the dissolution medium than the pure drug. It can be assumed that, in the early stages of dissolution process, the β -CD molecules operate locally on the hydrodynamic layer surrounding the drug particles. This action results in an *in situ* inclusion process, which produces a rapid increase in the amount of dissolved drug.

CONCLUSION

The results suggest that β -CD forms inclusion complexes with carvedilol by both the kneading and co-precipitation techniques, with a dramatic improvement in drug dissolution rate relative to the drug or the β -CD /drug physical mixture. The release profile of inclusion complexes prepared by co-precipitation techniques was better compared to that of complexes prepared by kneading method.

REFERENCES

- Jug, M. and Becirevic-Lacan, M. 2004. Multicomponent complexes of piroxicam with cyclodextrins and hydroxypropyl methylcellulose. *Drug Dev. Ind. Pharm.* **30**, 1051-1060.

2. Uekama, K., Hirayama, F. and Irie, T. 1998. Cyclodextrin drug carriers systems. *Chem. Rev.* **98**, 2045-2076.
3. Manca, M.L., Zaru, M., Ennas, M., Valenti, D. Sinico, C. Loy, G. and Fadda, A.M. 2005. Diclofenac- β -cyclodextrin binary systems: physicochemical characterization and *in vitro* dissolution and diffusion studies. *AAPS Pharm. Sci. Tech.* **6**, E464-E472.
4. Thompson, D.O. 1997. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. *Crit. Rev. Ther. Drug Carrier. Syst.* **14**, 1-104.
5. Masson, M., Loftsson, T., Masson, G. and Stefansson, E.S. 1999. Cyclodextrins as permeation enhancer some theoretical evaluations and *in vitro* testing. *J. Control. Release.* **59**, 107-118.
6. Chowdary, K.P.R. and Srinivas, S.V. 2006. Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl β -cyclodextrin. *AAPS Pharm. Sci. Tech.* **7**, E1- E6.
7. Loftsson, T. and Brewster, M.E. 1996. Pharmaceutical applications of cyclodextrins, I: drug solubilization and stabilization. *J. Pharm. Sci.* **85**, 1017-1025.
8. Rajewski, R.A. and Stella, V.J. 1996. Pharmaceutical applications of cyclodextrins, II: *in vivo* drug delivery. *J. Pharm. Sci.* **85**, 1142-1169.
9. Larsen, K.L. 2002. Large cyclodextrins. *J. Inclusion Phenom. Macro. Chem.* **43**, 1-13.
10. Ruffolo Jr., R.R., Boyle, D.A., Venuti, R.P. and Lukas, M.A. 1993. Preclinical and clinical pharmacology of carvedilol. *J. Hum. Hypertens.* **7**, S2-S15.
11. Ruffolo Jr., R.R., Gellai, M., Hieble, J.P. Willette, R.N. and Nichols, A.J. 1990. The pharmacology of carvedilol. *Eur. J. Clin. Pharmacol.* **38**, S82-S88.
12. Baboota, S., Dhaliwal, M. and Kohli, K. 2005. Physicochemical Characterization, *In vitro* dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. Preparation and properties of rofecoxib hydroxypropyl β -cyclodextrin inclusion complex: a technical note. *AAPS Pharm. Sci. Tech.* **6**, E83-E90.
13. Longxiao, V. and Xiaocui, W. 2007. Improved dissolution of oleanolic acid with ternary solid dispersions. *AAPS Pharm. Sci. Tech.* **8**, E1-E5.
14. Cunha-Filho, M.S.S., Dacunha-Marinho, B., Torres-Labandeira, J.J., Martinez-Pacheco, R. and Landin, M. 2007. Characterization of β -lapachone and methylated β -cyclodextrin solid-state systems. *AAPS Pharm. Sci. Tech.* **8**, E1-E10.
15. Higuchi, T. and Connors, K.A. 1965. Phase-solubility techniques. *Adv. Anal. Chem. Instr.* **14**, 117-212, 1965.
16. Patel, S.G. and Rajput, S.J. 2009. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. *AAPS Pharm. Sci. Tech.* **10**, 660-669.
17. Cirri, M., Mura, P., Rabasco, A.M., Gines, J.M., Moyano, J.R. and Gonzalez-Rodriguez, M.L. 2004. Characterization of ibuprofen binary and ternary dispersions with hydrophilic carriers. *Drug Dev. Ind. Pharm.* **30**, 65-74.